Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100645 | 1.00 | MAPK14 (0.48) | MAPK14CSNK1DMAPK11PRKCIMAPK1 | |
| Trifluoroacetic Acid SCHEMBL4092178 | 0.90 | MAPK14 (0.41) | MAPK14CSNK1DMAPK11PRKCIMAPK1 | |
| SCHEMBL29540449 | 0.87 | PRKCI (0.46) | MAPK14CSNK1DMAPK11PRKCIAKT2 | |
| SCHEMBL28055281 | 0.87 | PRKCI (0.46) | PRKCIMAPK1AKT2NUDT1AXL | |
| SCHEMBL102456 | 0.87 | PRKCI (0.46) | MAPK14CSNK1DMAPK11PRKCIAKT2 | |
| SCHEMBL100939 | 0.87 | JAK2 (0.52) | PRKCIMAPK1AKT2NUDT1IKBKB | |
| SCHEMBL29540619 | 0.87 | JAK2 (0.52) | PRKCIMAPK1AKT2NUDT1IKBKB | |
| SCHEMBL100644 | 0.84 | MAPK1 (0.47) | PRKCIMAPK1AKT2ROCK1 | |
| SCHEMBL29540798 | 0.84 | MAPK1 (0.47) | PRKCIMAPK1AKT2ROCK1 | |
| SCHEMBL99492 | 0.84 | PRKCI (0.43) | PRKCIAKT2NUDT1AXLIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | MAPK14 362/4885CSNK1D 1611/4885MAPK11 550/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | MAPK14 362/4885CSNK1D 1611/4885MAPK11 550/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | MAPK14 362/4885CSNK1D 1611/4885MAPK11 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.